Evolus, Inc. (NASDAQ:EOLS – Get Free Report) rose 5.9% on Friday . The company traded as high as $14.49 and last traded at $14.40. Approximately 220,301 shares were traded during trading, a decline of 62% from the average daily volume of 577,022 shares. The stock had previously closed at $13.60.
Analyst Upgrades and Downgrades
Several research analysts have commented on EOLS shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Thursday, June 20th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, August 1st. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, August 1st.
Get Our Latest Research Report on Evolus
Evolus Price Performance
Insiders Place Their Bets
In other news, Director Vikram Malik sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $12.96, for a total value of $97,200.00. Following the completion of the transaction, the director now owns 246,514 shares in the company, valued at approximately $3,194,821.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Evolus news, Director Vikram Malik sold 7,500 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $12.96, for a total value of $97,200.00. Following the completion of the transaction, the director now owns 246,514 shares in the company, valued at $3,194,821.44. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Moatazedi sold 155,278 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $12.92, for a total value of $2,006,191.76. Following the transaction, the insider now directly owns 533,349 shares of the company’s stock, valued at approximately $6,890,869.08. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Evolus
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Quest Partners LLC bought a new stake in shares of Evolus in the 2nd quarter worth approximately $43,000. Quarry LP purchased a new position in Evolus during the second quarter valued at $54,000. AJOVista LLC bought a new stake in Evolus in the fourth quarter worth $70,000. Tradition Wealth Management LLC grew its stake in shares of Evolus by 44.8% in the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock worth $84,000 after acquiring an additional 2,475 shares during the last quarter. Finally, Sierra Summit Advisors LLC bought a new position in shares of Evolus during the fourth quarter valued at $119,000. Institutional investors own 90.69% of the company’s stock.
About Evolus
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Articles
- Five stocks we like better than Evolus
- Energy and Oil Stocks Explained
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- What Does a Stock Split Mean?
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Upcoming IPO Stock Lockup Period, Explained
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.